Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise against rare liver virus

NCT ID NCT06907290

Disease control Sponsor: Mirum Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called BJT-778 for people with chronic hepatitis delta, a serious liver infection. About 150 adults will either start the drug right away or wait 24 weeks before starting. The goal is to see if the drug can lower the virus level and improve liver health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing and able to provide written informed consent. * Chronic HDV infection * HDV RNA \>500 IU/mL at Screening. * Abnormal ALT (\>upper limit of normal) at Screening. * Willing to take or already taking HBV nucleos(t)ide therapy Exclusion Criteria: * Pregnant or nursing females. * Unwilling to comply with contraception requirements during the study. * Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy * Presence of other liver disease(s) (does not include HBV or HDV infection) such as non-alcoholic steatohepatitis (NASH), alcohol associated hepatitis, cholestatic liver disease, hepatocellular carcinoma. * Clinical hepatic decompensation (i.e., ascites, encephalopathy variceal hemorrhage). * Solid organ or bone marrow transplantation Note: other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatitis D infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis D virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hepatitis D infection

Contacts and locations

Locations

  • 001 Auckland

    Auckland, New Zealand

  • 101 Camperdown

    Camperdown, Australia

  • 102 Melbourne

    Melbourne, Victoria, Australia

  • 104 Liverpool

    Liverpool, Australia

  • 110 Kyiv

    Kyiv, 01001, Ukraine

  • 181 Tbilisi

    Tbilisi, 0105, Georgia

  • 182 Tbilisi

    Tbilisi, Georgia

  • 183 Tbilisi

    Tbilisi, 0105, Georgia

  • 191 Istanbul

    Istanbul, Istanbul, Turkey (Türkiye)

  • 211 Israel

    Beersheba, Israel

  • 212 Haifa

    Haifa, Haifa District, Israel

  • 221 Karachi City

    Karachi, Karachi, Pakistan

  • 231 Toronto

    Toronto, Ontario, Canada

  • 233 Calgary

    Calgary, Calgary, Canada

  • 234 Alberta

    Edmonton, Edmonton, T6G 2G5, Canada

  • 235 Montreal

    Montreal, Quebec, Canada

  • 241, Massachusetts

    Boston, Massachusetts, 02114, United States

  • 242 Huntington Beach

    Huntington Beach, California, 92647, United States

  • 244 Los Angeles

    Los Angeles, California, 90033, United States

  • 245 New York

    New York, New York, 10007, United States

  • 247 Garden Grove

    Garden Grove, California, 92840, United States

  • 248 Lowa

    Cities in Iowa, Iowa, 52242, United States

  • 249 San Antonio

    San Antonio, Texas, 78215, United States

  • 250 Miami

    Miami, Florida, 33166, United States

  • 251, Illinois

    Chicago, Illinois, 60612, United States

  • 252 Long Beach

    Long Beach, California, 90805, United States

  • 253 New York

    New York, New York, 10075, United States

  • 254 Baltimore

    Baltimore, Maryland, 21287, United States

  • 255 New York

    New York, New York, 10075, United States

  • 256 New York

    New York, New York, 10065, United States

  • 257 Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • 291 Belgrade

    Belgrade, Belgrade, Serbia

  • 702 Bulgaria

    Sofia, Bulgaria

  • 703 Sliven

    Sliven, Silven, 8800, Bulgaria

  • 704 Stara Zagora

    Stara Zagora, Bulgaria

  • 705 Plovdiv

    Plovdiv, Bulgaria

  • 706 Sofia

    Sofia, Bulgaria

  • 901 Chisinau

    Chisinau, Moldova

More trials for these conditions

Other studies related to the condition(s) this trial covers.